Move beyond PEG in nucleic acid delivery
Our proprietary PEG-free lipid nanoparticle platform is designed to overcome the limitations of PEGylated LNPs, enabling improved efficacy, repeat dosing, and organ targeting.
About Pamphora
Advancing Nucleic Acid Delivery
Pamphora is developing a next-generation PEG-free lipid nanoparticle (LNP) platform for nucleic acid delivery. Our technology is designed to overcome key limitations associated with current PEGylated LNP systems, including reduced efficacy during repeat dosing and unwanted immune responses.
By enabling improved delivery performance, repeat administration, and expanded organ targeting potential, Pamphora aims to support the next wave of mRNA and nucleic acid therapeutics across a wide range of applications.
THE PROBLEM
Current mRNA Delivery Systems Have Limitations
Many nucleic acid therapies rely on PEGylated lipid nanoparticles (LNPs) for delivery. However, these systems can face major challenges during repeated dosing, including reduced efficacy, immune responses, and limited organ targeting. These limitations can impact therapeutic performance and restrict broader clinical applications.
Reduced Efficacy Over Time
Repeated administration can reduce the effectiveness of current PEGylated delivery systems, limiting long-term therapeutic performance.
PEG-Associated Immune Responses
PEG components may trigger pseudo-allergic reactions and immune recognition, creating safety and tolerability concerns.
Limited Organ Targeting
Many existing LNP systems are primarily liver-focused, making delivery to other tissues and cell types more challenging.
Help Shape the Future of PEG-Free Nucleic Acid Delivery
Share your insights on current challenges in mRNA and nucleic acid delivery, including repeat dosing, PEG-associated limitations, and extrahepatic targeting.
OUR SOLUTION
A PEG-Free Platform for Next-Generation Nucleic Acid Delivery
Pamphora’s proprietary PEG-free lipid nanoparticle platform is designed to overcome key limitations of current delivery systems. By improving repeat dosing performance, reducing PEG-associated responses, and enabling broader targeting potential, we aim to support the future of mRNA and nucleic acid therapeutics.
PEG-free by design
Built for repeat administration
Expanded targeting potential
Seamless platform integration
CONTACT US
Explore Partnership & Collaboration Opportunities
Interested in learning more about Pamphora’s PEG-free lipid nanoparticle platform?
Whether you’re developing nucleic acid therapeutics, exploring formulation technologies, or looking for potential collaboration opportunities, we’d be happy to hear from you.